Oncology News | pharmaphorum

News

BMS signs $475m cancer immunotherapy deal with Dragonfly

Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA to decide on TG Therapeutics' lymphoma drug early next y...

The FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against a combination therapy from Bristol-Myers Squibb and Roche.

News

Pieris begins gastric cancer combination trial with Lilly's ...

US biotech Pieris Pharmaceuticals has begun a collaboration and supply agreement with Eli Lilly, trialling its cancer drug PRS-343 in combination with the big pharma’s Cyramza (ramucirumab)

News

BMS’ Opdivo aces trial in asbestos-linked lung cancer

Bristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, getting one up over rival checkpoint inhibitor Keytr

News

Roche’s Tecentriq flunks triple-negative breast cancer trial

Roche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been dashed by a late-stage trial failure looking at the drug i

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...

Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.

BMS signs $475m cancer immunotherapy deal with Dragonfly

FDA to decide on TG Therapeutics' lymphoma drug early next y...

Pieris begins gastric cancer combination trial with Lilly's ...

BMS’ Opdivo aces trial in asbestos-linked lung cancer

Roche’s Tecentriq flunks triple-negative breast cancer trial

Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...

Simple blood test could aid in global TB fight

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks